- Types of Eczema
- Child Eczema
- Causes & Triggers
- Related Conditions
- Living with Eczema
- Eczema Products
- Get Involved
Understanding AD’s impact to improve your quality of life July 19, 2016 — People living with atopic dermatitis (AD), the most common and chronic form of eczema, know first-hand the burden AD has on both individuals and families. The impacts reach far beyond the serious effects of the disease symptoms such as itch, pain, and […]
Eczema affects more than 30 million people in the United States. The most common and chronic form of eczema is known as atopic dermatitis (AD). There is currently no cure for eczema or AD. To help raise awareness about the serious impact AD has on individuals and families, the National Eczema Association (NEA) has joined […]
We asked, you answered. The verdict? People living with eczema want more information and more options. This past January, many of you responded to a 6-question online survey to evaluate patient satisfaction and the role of doctors in the treatment of the most serious form of eczema, atopic dermatitis (AD). We learned that the vast majority of […]
June 9, 2016 – On Monday, June 6, 2016 the pharmaceutical companies Regeneron and Sanofi, reported positive results for the Phase 3 the clinical trial of the new biologic drug, dupilumab, when used in conjunction with a topical corticosteroid by adults to treat moderate-to-severe atopic dermatitis (AD).
We all play an important role, especially patients, in bringing new treatments to those that need them. Research is like a relay race that scientists can only take so far, and at some point, they must hand the baton to patients to engage in clinical trials to help bring the treatment to reality. The National […]
Increasingly, the concept of leaky gut is being touted by alternative and holistic practitioners as being fundamentally important in many chronic illnesses. By Peter A. Lio and Karan Lal, MS-4 It is now well accepted that skin barrier dysfunction is implicated in a variety of important inflammatory skin diseases including acne, atopic dermatitis, and psoriasis.1 […]
February 11, 2016 – Late last month, NEA’s Board of Directors gathered together for the annual NEA Board retreat in San Francisco, California. This year’s retreat focused on both celebrating 2015 successes, and sharing a number of exciting 2016 initiatives that will advance NEA’s Roadmap strategic plan goals.
February 10, 2016 – In January, Anacor Pharmaceuticals, Inc. announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of crisaborole topical ointment, 2%.
NEA formed a Scientific Advisory Committee Task Force to conduct a systematic review of topical corticosteroid withdrawal/topical steroid addiction in patients with atopic dermatitis and other dermatoses, and created a NEA education announcement on Topical Steroid Addiction/Withdrawal.